Target Name: RBM14
NCBI ID: G10432
Review Report on RBM14 Target / Biomarker Content of Review Report on RBM14 Target / Biomarker
RBM14
Other Name(s): OTTHUMP00000205221 | TMEM137 | transcriptional coactivator CoAZ | Paraspeckle protein 2 | MGC15912 | Synaptotagmin-interacting protein | SYTIP1 | RRM-containing coactivator activator/modulator | CoAA | RBM14 variant 1 | OTTHUMP00000179145 | RBM14/RBM4 fusion | paraspeckle protein 2 | DKFZp779J0927 | RNA binding motif protein 14 | RBM14-RBM4 readthrough | RNA binding motif protein 14, transcript variant 1 | MGC31756 | RNA-binding protein 14 | RBM14_HUMAN | synaptotagmin-interacting protein | COAA | Coactivator activator | PSP2 | RNA-binding protein 14 (isoform 1) | SIP | transmembrane protein 137 | Transmembrane protein 137 | RNA-binding motif protein 14 | SYT-interacting protein | RBM14-RBM4 protein

RBM14: Potential Drug Targets and Research

RBM14 (ResidualBodyM R14), also known as OTTHUMP00000205221, is a protein that is expressed in various tissues of the human body, including the brain, muscle, and heart. It is a key regulator of cell death and has been implicated in a number of diseases, including neurodegenerative disorders, cancer, and traumatic injury. In this article, we will discuss the potential drug targets of RBM14 and the research being done to target this protein.

Potential Drug Targets

RBM14 has several potential drug targets, including:

1. neurodegenerative disorders: RBM14 has been implicated in the development and progression of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Studies have shown that RBM14 levels are elevated in individuals with these disorders, and that inhibiting RBM14 may be a potential therapeutic approach.
2. cancer: RBM14 has been found to be overexpressed in a variety of cancer types, including breast, ovarian, and prostate cancer. Experiments have shown that inhibiting RBM14 may be a promising strategy for cancer treatment.
3. traumatic injury: RBM14 is also expressed in the brains of individuals who have experienced traumatic injury, and studies have suggested that it may play a role in the development of chronic pain and neuropsychiatric disorders after injury. Targeting RBM14 may be a potential approach to treating traumatic injury and related conditions.

Drug Development

While there are currently no FDA-approved drugs that specifically target RBM14, there is a lot of interest in developing compounds that can inhibit its activity. Researchers are exploring a variety of approaches to achieve this goal, including small molecule inhibitors, RNA-based therapeutics, and protein-based therapeutics.

One approach being explored is the use of small molecules that can inhibit the activity of RBM14. Researchers have synthesized a number of compounds that are known to inhibit the activity of RBM14, and are testing these compounds for their potential therapeutic activity. These compounds range from small molecules that are derived from natural compounds to synthetic compounds that are specifically designed to inhibit RBM14.

Another approach being explored is the use of RNA-based therapeutics to target RBM14. Researchers have developed RNA-based drugs that can be used to treat a variety of conditions, including neurodegenerative disorders. By using RNA-based therapeutics to deliver small molecules to specific cells, researchers hope to be able to treat a wide range of conditions.

Protein-based therapeutics are also being explored as a potential approach to targeting RBM14. Researchers have developed proteins that can be used to deliver small molecules to specific cells, and are using these proteins to treat a variety of conditions. While the use of protein-based therapeutics can be a powerful approach to treating disease, there are currently no FDA-approved drugs that are specifically designed to target RBM14.

Conclusion

RBM14 is a protein that is expressed in various tissues of the human body, and has been implicated in a number of diseases. While currently there are no FDA-approved drugs that specifically target RBM14, there is a lot of interest in developing compounds that can inhibit its activity. Researchers are exploring a variety of approaches to achieve this goal, including the use of small molecules, RNA-based therapeutics, and protein-based therapeutics. With further research, we may be able to develop compounds that can effectively treat a wide range of diseases that are caused by the over activity of RBM14.

Protein Name: RNA Binding Motif Protein 14

The "RBM14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBM14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RBM14-RBM4 | RBM15 | RBM15-AS1 | RBM15B | RBM17 | RBM17P1 | RBM18 | RBM19 | RBM20 | RBM22 | RBM22P1 | RBM23 | RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1 | RCAN2 | RCAN3 | RCAN3AS | RCBTB1 | RCBTB2 | RCC1 | RCC1L | RCC2 | RCCD1 | RCE1 | RCHY1 | RCL1 | RCN1 | RCN1P2 | RCN2 | RCN3 | RCOR1 | RCOR2 | RCOR3 | RCSD1 | RCVRN | RD3 | RD3L | RDH10